VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Status:
Completed
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
In this Phase I study, the study team will evaluate the safety of Valproic Acid (VPA)
expanded cord blood stem cells defined by the lack of serious infusion reactions or graft
failure in patients with hematological malignancies undergoing umbilical cord blood
transplantation. Moreover, the study team will also evaluate time to neutrophil and platelet
engraftment as well as transplant related outcomes such as graft versus host disease (GVHD),
treatment related mortality (TRM), and overall survival (OS).